101
|
Affiliation(s)
- T. J. Dolan
- National Institute for Fusion Science, Toki, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, Toki, Japan
| | - A. Sagara
- National Institute for Fusion Science, Toki, Japan
| |
Collapse
|
102
|
Yamazaki K, Sakai K, Ohashi Y, Nihei H, Itabashi T, Muramatsu M, Kawamura T, Shishido S, Aikawa A. Similar Anemic Control Between Chronic Kidney Diseases in Patients With and Without Transplantation on Entry to Dialysis. Transplant Proc 2017; 49:57-60. [PMID: 28104159 DOI: 10.1016/j.transproceed.2016.11.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Transplant recipients are supposedly in a more anemic, catabolic, and even inflammatory state at re-entering hemodialysis due to chronic rejection. The goal of this study was to clarify how transplant recipients can re-enter dialysis safely by focusing on control of anemia. METHODS From 2012 to 2014, a total of 29 transplant recipients re-entered hemodialysis because of chronic rejection (ie, the chronic kidney disease with transplant [CKDT] group). At the same time, in 2014, a total of 30 patients with chronic kidney disease without transplantation entered dialysis as the control group (ie, the CKD group). CKDT recipients (mean ± standard deviation age, 41.9 ± 11.8 years; 18 male subjects, 10 female subjects; frequency of diabetes, 10%; duration of graft survival, 12.5 ± 4.3 years) were younger and fewer had diabetes compared with the CKD group (age, 53.2 ± 10.5 years; 21 male subjects, 9 female subjects; frequency of diabetes, 36%). Patient characteristics at entering dialysis in both groups were analyzed according to retrospective chart review. RESULTS At entering dialysis, there were no significant differences between the CKD and CKDT groups in terms of the following: dose of darbepoetin; concentrations of hemoglobin, albumin, and C-reactive protein; cardiothoracic ratio; blood urea nitrogen and creatinine levels; estimated glomerular filtration rate; initial ultrafiltration; and duration of hospitalization for initiation of dialysis. The only difference between groups was mean weight at entry to dialysis (CKDT group, 58.5 ± 15.1 kg; CKD group, 67.1 ± 14.8 kg; P = .03). The darbepoetin dose per kilogram of weight did not differ between groups (CKDT, 2.28 ± 2.03 μg/kg; CKD, 2.12 ± 1.6 μg/kg; P = .95) in the final month before entry to dialysis. CONCLUSIONS Safe re-initiation of dialysis is important for recipient survival. Although anemia is supposedly higher in transplant recipients due to immunosuppression, this single-center analysis found no difference in anemia in CKD with or without transplantation, caused by good use of erythropoietin-stimulating agents in both groups.
Collapse
Affiliation(s)
- K Yamazaki
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - K Sakai
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
| | - Y Ohashi
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - H Nihei
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - T Itabashi
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - M Muramatsu
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - T Kawamura
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - S Shishido
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| | - A Aikawa
- Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan
| |
Collapse
|
103
|
Okutsu K, Yamazaki K, Ohshimo K, Misaizu F. Photofragment ion imaging from mass-selected Mg +BrCH 3 complex: Dissociation mechanism following photoinduced charge transfer. J Chem Phys 2017; 146:024301. [PMID: 28088160 DOI: 10.1063/1.4973386] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We have observed fragment ion images produced by ultraviolet photodissociation of Mg+BrCH3 complex ions using a reflectron time-of-flight mass spectrometer combined with an imaging detector. The BrCH3+ fragment ion was produced after the 266-nm excitation of Mg+BrCH3. In the image of the BrCH3+ ions, a split distribution was observed parallel to the polarization direction of the photolysis laser. In calculated potential energy curves, we found a repulsive potential correlated with a dissociation limit of Mg + BrCH3+: The calculation results indicate that the dissociation and the charge transfer occurred via non-adiabatic process after the 52A' ← 12A' photoexcitation. The obtained energy and angular distributions of BrCH3+ photofragments were consistent with the fast BrCH3+ formation process on the repulsive potential energy curve.
Collapse
Affiliation(s)
- Kenichi Okutsu
- Department of Chemistry, Graduate School of Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | - Kenichiro Yamazaki
- Department of Chemistry, Graduate School of Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | - Keijiro Ohshimo
- Department of Chemistry, Graduate School of Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | - Fuminori Misaizu
- Department of Chemistry, Graduate School of Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| |
Collapse
|
104
|
Abstract
CD4+CD25+ regulatory T (Tr) cells are critical in regulating the immune response and thereby play an important role in the defense against infection and control of autoimmune diseases. Our previous studies demonstrated the involvement of autoimmune responses in periodontitis. The aim of this study was to identify CD4+CD25+ Tr cells in periodontitis tissues and compare them with those in gingivitis tissues. Immunohistological analysis of CD4, CD25, and CTLA-4 and the gene expression analysis of FOXP3, TGF-β1, and IL-10 on gingival biopsies revealed the presence of CD4+CD25+ Tr cells in all tissues. In periodontitis, the percentage of CD4+CD25+ Tr cells increased with increasing proportions of B-cells relative to T-cells. FOXP3, a characteristic marker for CD4+CD25+ Tr cells, TGF-β1 and IL-10 were expressed more highly in periodontitis compared with gingivitis. These findings suggest that CD4+CD25+ Tr cells and possibly other regulatory T-cell populations do exist and may play regulatory roles in periodontal diseases.
Collapse
Affiliation(s)
- T Nakajima
- Periodontology and Immunology, Department of Oral Health and Welfare, Niigata University Faculty of Dentistry, 5274 Gakkocho 2-ban-cho, Niigata 951-8514, Japan
| | | | | | | | | | | | | |
Collapse
|
105
|
Yamazaki K, Kito Y, Esaki T, Satake H, Taniguchi H, Tsuda T, Denda T, Moriwaki T, Mori K. 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumabas first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00374-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
106
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
107
|
Yamazaki K, Kito Y, Esaki T, Satake H, Taniguchi H, Tsuda T, Denda T, Moriwaki T, Mori K. 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
108
|
Chung H, Chao Y, Lee KW, Kudo M, Yen CJ, Kim T, Yamazaki K, Shih JY, Kim SW, Sohn JH, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Muro K. 153P Ramucirumab safety in East Asian (EA) compared to non-EA patients: A meta-analysis of adverse events (AEs) in 6 global, randomized, double-blind, phase 3 clinical trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
109
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
110
|
Ishikawa H, Masujima H, Tanaka R, Kamoshida T, Shino M, Yamazaki K. 526P A retrospective study on the protective effect of nonsteroidal anti-inflammatory drugs on panitumumab-related skin symptoms. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw599.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
111
|
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 2016; 27:2082-2090. [PMID: 27573561 PMCID: PMC5091322 DOI: 10.1093/annonc/mdw402] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 07/27/2016] [Accepted: 08/10/2016] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and progression-free survival (PFS) (HR = 0.793, P < 0.0005) compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma (mCRC) patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. Since some patient or disease characteristics could be associated with differential efficacy or safety, prespecified subgroup analyses were undertaken. This report focuses on three of the most relevant ones: KRAS status (wild-type versus mutant), age (<65 versus ≥65 years), and time to progression (TTP) on first-line therapy (<6 versus ≥6 months). PATIENTS AND METHODS OS and PFS were evaluated by the Kaplan-Meier analysis, with HR determined by the Cox proportional hazards model. Treatment-by-subgroup interaction was tested to determine whether treatment effect was consistent between subgroup pairs. RESULTS Patients with both wild-type and mutant KRAS benefited from ramucirumab + FOLFIRI treatment over placebo + FOLFIRI (interaction P = 0.526); although numerically, wild-type KRAS patients benefited more (wild-type KRAS: median OS = 14.4 versus 11.9 months, HR = 0.82, P = 0.049; mutant KRAS: median OS = 12.7 versus 11.3 months, HR = 0.89, P = 0.263). Patients with both longer and shorter first-line TTP benefited from ramucirumab (interaction P = 0.9434), although TTP <6 months was associated with poorer OS (TTP ≥6 months: median OS = 14.3 versus 12.5 months, HR = 0.86, P = 0.061; TTP <6 months: median OS = 10.4 versus 8.0 months, HR = 0.86, P = 0.276). The subgroups of patients ≥65 versus <65 years also derived a similar ramucirumab survival benefit (interaction P = 0.9521) (≥65 years: median OS = 13.8 versus 11.7 months, HR = 0.85, P = 0.156; <65 years: median OS = 13.1 versus 11.9 months, HR = 0.86, P = 0.098). The safety profile of ramucirumab + FOLFIRI was similar across subgroups. CONCLUSIONS These analyses revealed similar efficacy and safety among patient subgroups with differing KRAS mutation status, longer or shorter first-line TTP, and age. Ramucirumab is a beneficial addition to second-line FOLFIRI treatment for a wide range of patients with mCRC. TRIAL REGISTRATION ClinicalTrials.gov, NCT01183780.
Collapse
Affiliation(s)
- R Obermannová
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - E Van Cutsem
- University Hospitals Leuven and KU Leuven, Leuven, Belgium
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - G Bodoky
- Department of Oncology, St László Hospital, Budapest, Hungary
| | - J Prausová
- Onocology Clinic, Charles University, Prague, Czech Republic
| | - R Garcia-Carbonero
- Department of Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - T Ciuleanu
- Institutul Oncologic Ion Chiricuta and UMF, Cluj-Napoca, Romania
| | - P Garcia Alfonso
- Department of Oncology, Hospital General Universitario Gregorio Maraňón, Madrid, Spain
| | - D Portnoy
- The West Clinic-University of Tennessee Health Sciences Center, Memphis
| | - A Cohn
- Rocky Mountain Cancer Center, Denver, USA
| | - K Yamazaki
- Department of Gastrointestinal Oncology, Shizouka Cancer Center, Shizouka, Japan
| | - P Clingan
- Southern Medical Day Care Centre, Wollongong, NSW, Australia
| | - S Lonardi
- Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy
| | - T W Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - L Yang
- Eli Lilly and Company, Bridgewater, USA
| | - F Nasroulah
- Eli Lilly and Company, Buenos Aires, Argentine Republic
| | - J Tabernero
- Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
112
|
Yoh K, Doi T, Yamazaki K, Okusaka T, Ikeda M, Guo W, Nakamura A, Ohtsu A. Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors or hepatocellular carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw521.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
113
|
Kawakami T, Tsushima T, Hayashi K, Shirasu H, Kawahira M, Kawai S, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Machida N, Yamazaki K, Yokota T, Fukutomi A, Onozawa Y, Yasui H. Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
114
|
Sukawa Y, Nosho K, Miura Y, Takano T, Ito M, Yonesaka K, Mori M, Tokunaga S, Kawada J, Okuda H, Sakamoto T, Hirashima Y, Uchino K, Miyata Y, Yoshimura K, Yamazaki K, Hironaka S, Boku N, Hyodo I, Muro K. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
115
|
Yamaguchi K, Komatsu Y, Oki E, Yoshino T, Yamazaki K, Shibuya K, Oba K, Kato T. APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
116
|
Yamazaki K, Yoshino T, Shinozaki E, Komatsu Y, Tsuji Y, Nishina T, Baba H, Denda T, Sugimoto N, Tsuji A, Yamaguchi K, Takayama T, Shimada Y, Hamamoto Y, Muro K, Gotoh M, Tanase T, Ohtsu A. Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
117
|
Nishina T, Kuboki Y, Shinozaki E, Fukuoka S, Kajiwara T, Shitara K, Yamaguchi K, Komatsu Y, Yuki S, Yamazaki K, Hara H, Mochizuki N, Fukutani M, Hasegawa H, Matsuda S, Wakabayashi M, Nomura S, Sato A, Ohtsu A, Yoshino T. A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
118
|
Nishita Y, Abramov AV, Kosintsev PA, Lin LK, Watanabe S, Yamazaki K, Kaneko Y, Masuda R. Genetic variation of the MHC class II DRB genes in the Japanese weasel, Mustela itatsi, endemic to Japan, compared with the Siberian weasel, Mustela sibirica. ACTA ACUST UNITED AC 2016; 86:431-42. [PMID: 26593752 DOI: 10.1111/tan.12700] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 10/07/2015] [Accepted: 10/21/2015] [Indexed: 01/19/2023]
Abstract
Major histocompatibility complex (MHC) genes encode proteins that play a critical role in vertebrate immune system and are highly polymorphic. To further understand the molecular evolution of the MHC genes, we compared MHC class II DRB genes between the Japanese weasel (Mustela itatsi), a species endemic to Japan, and the Siberian weasel (Mustela sibirica), a closely related species on the continent. We sequenced a 242-bp region of DRB exon 2, which encodes antigen-binding sites (ABS), and found 24 alleles from 31 M. itatsi individuals and 17 alleles from 21 M. sibirica individuals, including broadly distributed, species-specific and/or geographically restricted alleles. Our results suggest that pathogen-driven balancing selection have acted to maintain the diversity in the DRB genes. For predicted ABS, nonsynonymous substitutions exceeded synonymous substitutions, also indicating positive selection, which was not seen at non-ABS. In a Bayesian phylogenetic tree, two M. sibirica DRB alleles were basal to the rest of the sequences from mustelid species and may represent ancestral alleles. Trans-species polymorphism was evident between many mustelid DRB alleles, especially between M. itatsi and M. sibirica. These two Mustela species divided about 1.7 million years ago, but still share many MHC alleles, indicative of their close phylogenetic relationship.
Collapse
Affiliation(s)
- Y Nishita
- Department of Biological Sciences, Faculty of Science, Hokkaido University, Sapporo, Japan
| | - A V Abramov
- Zoological Institute, Russian Academy of Sciences, Moscow, Russia
| | - P A Kosintsev
- Institute of Plant & Animal Ecology, Russian Academy of Sciences, Moscow, Russia
| | - L-K Lin
- Department of Life Science, Tunghai University, Taichung, Taiwan
| | - S Watanabe
- Seian University of Art and Design, Otsu, Japan
| | - K Yamazaki
- Forest Ecology Laboratory, Department of Forest Science, Faculty of Regional Environmental Science, Tokyo University of Agriculture, Fuchu, Japan
| | - Y Kaneko
- Department of Ecoregion Science, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Japan
| | - R Masuda
- Department of Biological Sciences, Faculty of Science, Hokkaido University, Sapporo, Japan
| |
Collapse
|
119
|
Soki H, Abo K, Yamazaki K, Kojima T, Oda T, Uzawa Y, Kikuchi K. [First Report of Intraorbital Abscess Caused by Candida allociferrii and Specific PCR for Differentiating Stephanoascus ciferrii Complex Species]. Med Mycol J 2016; 56:E9-14. [PMID: 26073792 DOI: 10.3314/mmj.56.e9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We present a rare case of intraorbital abscess caused by Candida allociferrii, which was described as a new species of Stephanoascus ciferrii complex in 2002, in a patient after enucleation of choroidal melanoma. This strain showed resistance to itraconazole, and fluconazole. After debridement and topical use of amphotericin B, his wound abscess was disappeared. To our knowledge, this is the first C. allociferrii infection case in human.
Collapse
Affiliation(s)
- Hironobu Soki
- Department of Clinical Laboratory, Saitama Red Cross Hospital
| | | | | | | | | | | | | |
Collapse
|
120
|
Ha DT, Yamazaki K, Wang Y, Alcamí M, Maeda S, Kono H, Martín F, Kukk E. Fragmentation network of doubly charged methionine: Interpretation using graph theory. J Chem Phys 2016; 145:094302. [DOI: 10.1063/1.4962061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- D. T. Ha
- Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - K. Yamazaki
- Department of Chemistry, Graduate School of Science, Tohoku University, 980-8578 Sendai, Japan
- Department of Chemistry, Faculty of Science, Hokkaido University, Sapporo 060-0810, Japan
| | - Y. Wang
- Departamento de Química, Módulo 13, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto Madrileño de Estudios Avanzados en Nanociencia, Cantoblanco, 28049 Madrid, Spain
| | - M. Alcamí
- Departamento de Química, Módulo 13, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto Madrileño de Estudios Avanzados en Nanociencia, Cantoblanco, 28049 Madrid, Spain
| | - S. Maeda
- Department of Chemistry, Faculty of Science, Hokkaido University, Sapporo 060-0810, Japan
| | - H. Kono
- Department of Chemistry, Graduate School of Science, Tohoku University, 980-8578 Sendai, Japan
| | - F. Martín
- Departamento de Química, Módulo 13, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto Madrileño de Estudios Avanzados en Nanociencia, Cantoblanco, 28049 Madrid, Spain
- Condensed Matter Physics Center, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - E. Kukk
- Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| |
Collapse
|
121
|
Lonardi S, Cohn A, Yoshino T, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy D, Van Cutsem E, Yamazaki K, Clingan P, Polikoff J, Gao L, Yang L, Chang S, Ferry D, Nasroulah F, Tabernero J. Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
122
|
Yamazaki K. Systemic lupus erythematosus with hepatic aneurysm, Valsalva sinus aneurysm and associated polyangiitis: aneurysmal wall remodeling with dense fibrosis and calcification mediated by residual smooth muscle cells. Lupus 2016; 13:54-9. [PMID: 14870918 DOI: 10.1191/0961203304lu462cr] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Isolated case reports have demonstrated the combination of hepatic aneurysm and systemic lupus erythematosus (SLE). The author experienced a rare autopsy case of a 36-year old Japanese male with SLE, a hepatic aneurysm, a Valsalva sinus aneurysm and associated polyangiitis. In the histopathological and ultrastructural examinations of the postmortem organs, most of the angiitis lesions were in the scar phase associated with the histopathological features of collagenous fibrosis with the diminution of the smooth muscle cells and elastic fibre layers. Massive calcification was seen on the wall and obliterative changes in the lumen with calcified thrombi. In the dense collagenous stroma of the aneurysmal wall, residual atrophic smooth muscle cells with immunohistochemical (HHF35, alpha-smooth-muscle actin, vimentin and desmin almost-) and ultrastructural features (spindle-shapedcells with a few rER and rich intracytoplasmicfilaments with peripheraldense patches)were assumed to be involvedin the histogenesisof the aneurysmalwall. Massivecalcification and degenerationor dynamic remodelingof the extracellularmatrices in the aneurysmalwall might be mediated by the residual smooth muscle cells. It was suspected that the generalized polyangiitis as a complication of SLE might have involved the intrahepatic arteries and Valsalva sinus wall and subsequently generated the aneurysm.
Collapse
Affiliation(s)
- K Yamazaki
- Department of Pathology, Saiseikai Central Hospital, Tokyo, Japan.
| |
Collapse
|
123
|
Yoshino T, Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Fukutani M, Nakamoto M, Hasegawa H, Sugama A, Nomura S, Sato A, Ohtsu A. PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
124
|
Yoshino T, Shinozaki E, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. PD-014 Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.14] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
125
|
Tabernero J, Mayer Robert J, Ohtsu A, Yoshino T, Garcia-Carbonero R, Pastorino A, Peeters M, Winkler R, Makris L, Wahba M, Zaniboni A, Shimada Y, Yamazaki K, Komatsu Y, Hochster H, Lenz HJ, Falcone A, Tran B, Van Cutsem E. PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.25] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
126
|
Yao K, Uedo N, Muto M, Ishikawa H, Cardona HJ, Filho ECC, Pittayanon R, Olano C, Yao F, Parra-Blanco A, Ho SH, Avendano AG, Piscoya A, Fedorov E, Bialek AP, Mitrakov A, Caro L, Gonen C, Dolwani S, Farca A, Cuaresma LF, Bonilla JJ, Kasetsermwiriya W, Ragunath K, Kim SE, Marini M, Li H, Cimmino DG, Piskorz MM, Iacopini F, So JB, Yamazaki K, Kim GH, Ang TL, Milhomem-Cardoso DM, Waldbaum CA, Carvajal WAP, Hayward CM, Singh R, Banerjee R, Anagnostopoulos GK, Takahashi Y. Development of an E-learning System for the Endoscopic Diagnosis of Early Gastric Cancer: An International Multicenter Randomized Controlled Trial. EBioMedicine 2016; 9:140-147. [PMID: 27333048 PMCID: PMC4972485 DOI: 10.1016/j.ebiom.2016.05.016] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 05/15/2016] [Accepted: 05/16/2016] [Indexed: 01/06/2023] Open
Abstract
Background In many countries, gastric cancer is not diagnosed until an advanced stage. An Internet-based e-learning system to improve the ability of endoscopists to diagnose gastric cancer at an early stage was developed and was evaluated for its effectiveness. Methods The study was designed as a randomized controlled trial. After receiving a pre-test, participants were randomly allocated to either an e-learning or non-e-learning group. Only those in the e-learning group gained access to the e-learning system. Two months after the pre-test, both groups received a post-test. The primary endpoint was the difference between the two groups regarding the rate of improvement of their test results. Findings 515 endoscopists from 35 countries were assessed for eligibility, and 332 were enrolled in the study, with 166 allocated to each group. Of these, 151 participants in the e-learning group and 144 in the non-e-learning group were included in the analysis. The mean improvement rate (standard deviation) in the e-learning and non-e-learning groups was 1·24 (0·26) and 1·00 (0·16), respectively (P < 0·001). Interpretation This global study clearly demonstrated the efficacy of an e-learning system to expand knowledge and provide invaluable experience regarding the endoscopic detection of early gastric cancer (R000012039). This report establishes that an e-learning system on the Internet can improve the diagnostic ability of endoscopists. Countless endoscopists worldwide can access the system to learn how to make an endoscopic diagnosis of early gastric cancer. The e-learning system could be modified to provide education regarding endoscopic diagnosis in other organs.
This is the first report to demonstrate how an e-learning system based on the Internet can improve the diagnostic ability of gastrointestinal endoscopists worldwide. There is no limit to the number of endoscopists who can access the system and benefit from this opportunity to learn how to make an endoscopic diagnosis of early gastric cancer. This e-learning system could be modified to provide education regarding endoscopic diagnosis in other organs such as the large intestine and the esophagus, as well as the stomach. It may contribute to human welfare and health by reducing the mortality from gastrointestinal cancer.
Collapse
Affiliation(s)
- K Yao
- Fukuoka University Chikushi Hospital, Chikushino, Japan.
| | - N Uedo
- Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - M Muto
- Kyoto University, Kyoto, Japan
| | - H Ishikawa
- Kyoto Prefectural University of Medicine, Kyoto, Japan
| | | | | | - R Pittayanon
- King Chulalongkorn Memorial Hospital, The Thai Red Cross and Chulalongkorn University, Bangkok, Thailand
| | - C Olano
- Universidad de la República, Montevideo, Uruguay
| | - F Yao
- Peking Union Medical College Hospital, Beijing, China
| | - A Parra-Blanco
- School of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile
| | - S H Ho
- University of Malaya, Kuala Lumpur, Malaysia
| | - A G Avendano
- Hospital Rafael Angel Calderon Guardia, CCSS, San Jose, Costa Rica
| | - A Piscoya
- Universidad Peruana de Ciencias Aplicadas, Lima, Peru
| | - E Fedorov
- Russia National Medical University, Moscow University Hospital, N31, Moscow, Russian Federation
| | - A P Bialek
- Pomeranian Medical University, Szczecin, Poland
| | - A Mitrakov
- Nizhniy Novgorod Cancer Hospital, Nizhniy Novgorod, Russian Federation
| | - L Caro
- GEDyt Gastroenterologia diagnostica y tratamiento Inst afiliafa a la UBA Buenos Aires, Argentina
| | - C Gonen
- Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
| | - S Dolwani
- Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - A Farca
- The American British Cowdray Medical Center. Mexico City, Mexico
| | - L F Cuaresma
- Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru
| | - J J Bonilla
- i-gastro/Hospital Central de la Fuerza Aerea del Peru, Lima, Peru
| | - W Kasetsermwiriya
- Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
| | - K Ragunath
- NIHR Nottingham Digestive Disease Biomedical Research Unit, Queens Medical Centre, Nottingham University Hospital, Nottingham, United Kingdom
| | - S E Kim
- Kosin University College of Medicine, Busan, Republic of Korea
| | - M Marini
- Gastroenterology and Operative Endoscopy Unit, Siena University Hospital, Siena, Italy
| | - H Li
- Sichuan Provincial People's Hospital, Sichuan, Academy of Medical Sciences, Chengdu, China
| | | | - M M Piskorz
- Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
| | - F Iacopini
- Ospedale S. Giuseppe, ASL Roma 6, Albano L, Rome, Italy
| | - J B So
- National University of Singapore, Singapore, Singapore
| | - K Yamazaki
- University of Sao Paulo, Sao Paulo, Brazil
| | - G H Kim
- Pusan National University School of Medicine, Busan, Republic of Korea
| | - T L Ang
- Changi General Hospital, Singapore, Singapore
| | | | - C A Waldbaum
- Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
| | | | - C M Hayward
- Derriford Hospital, Plymouth, United Kingdom
| | - R Singh
- Lyell McEwin Hospital & University of Adelaide, Adelaide, Australia
| | - R Banerjee
- Asian Institute of Gastroenterology, Hyderabad, India
| | | | | |
Collapse
|
127
|
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 2016; 27:1539-46. [PMID: 27177863 DOI: 10.1093/annonc/mdw206] [Citation(s) in RCA: 157] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 05/09/2016] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab. PATIENTS AND METHODS WJOG4407G was a randomized, open-label, phase III trial conducted in Japan. Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI + Bev to mFOLFOX6 + Bev in progression-free survival (PFS), with an expected hazard ratio (HR) of 0.9 and non-inferiority margin of 1.25 (power 0.85, one-sided α-error 0.025). The secondary end points were response rate (RR), overall survival (OS), safety, and quality of life (QoL) during 18 months. This trial is registered to the University Hospital Medical Information Network, number UMIN000001396. RESULTS Among 402 patients enrolled from September 2008 to January 2012, 395 patients were eligible for efficacy analysis. The median PFS for FOLFIRI + Bev (n = 197) and mFOLFOX6 + Bev (n = 198) were 12.1 and 10.7 months, respectively [HR, 0.905; 95% confidence interval (CI) 0.723-1.133; P = 0.003 for non-inferiority]. The median OS for FOLFIRI + Bev and mFOLFOX6 + Bev were 31.4 and 30.1 months, respectively (HR, 0.990; 95% CI 0.785-1.249). The best overall RRs were 64% for FOLFIRI + Bev and 62% for mFOLFOX6 + Bev. The common grade 3 or higher adverse events were leukopenia (11% in FOLFIRI + Bev/5% in mFOLFOX6 + Bev), neutropenia (46%/35%), diarrhea (9%/5%), febrile neutropenia (5%/2%), peripheral neuropathy (0%/22%), and venous thromboembolism (6%/2%). The QoL assessed by FACT-C (TOI-PFC) and FACT/GOG-Ntx was favorable for FOLFIRI + Bev during 18 months. CONCLUSION FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus bevacizumab, as the first-line systemic treatment for mCRC. CLINICAL TRIALS NUMBER UMIN000001396.
Collapse
Affiliation(s)
- K Yamazaki
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka
| | - M Nagase
- Department of Clinical Oncology, Jichi Medical University, Shimotsuke
| | - H Tamagawa
- Department of Surgery, Osaka General Medical Center, Osaka
| | - S Ueda
- Department of Medical Oncology, Kinki University Faculty of Medicine, Higashiosaka
| | - T Tamura
- Department of Medical Oncology, Nara Hospital Kinki University Faculty of Medicine, Ikoma
| | - K Murata
- Department of Surgery, Suita Municipal Hospital, Suita
| | - T Eguchi Nakajima
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki
| | - E Baba
- Department of Comprehensive Clinical Oncology, Kyushu University Faculty of Medical Sciences, Fukuoka
| | - M Tsuda
- Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi
| | - T Moriwaki
- Division of Gastroenterology, University of Tsukuba, Tsukuba
| | - T Esaki
- Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - Y Tsuji
- Department of Medical Oncology, Tonan Hospital, Sapporo
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya
| | - K Taira
- Clinical Oncology, Osaka City General Hospital, Osaka
| | - T Denda
- Division of Gastroenterology, Chiba Cancer Center, Chiba
| | - S Funai
- Department of Surgery, Sakai Hospital Kinki University Faculty of Medicine, Sakai
| | - K Shinozaki
- Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima
| | - H Yamashita
- Department of Gastroenterology and Hepatology, Okayama Medical Center, Okayama
| | - N Sugimoto
- Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka
| | - T Okuno
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe
| | - T Nishina
- Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matuyama
| | - M Umeki
- Department of Surgery, Hyogo Prefectural Awaji Medical Center, Sumoto
| | - T Kurimoto
- Department of Gastrointestinal Oncology, Nagoya Kyoritsu Hospital, Nagoya
| | - T Takayama
- Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima
| | - A Tsuji
- Department of Medical Oncology, Kochi Health Sciences Center, Kochi
| | - M Yoshida
- Division of Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki
| | - A Hosokawa
- Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama
| | - Y Shibata
- Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki
| | - K Suyama
- Department of Medical Oncology, Toranomon Hospital, Tokyo
| | - M Okabe
- Department of Surgery, Kurashiki Central Hospital, Kurashiki
| | - K Suzuki
- Department of gastroenterology, Kushiro City General Hospital, Kushiro
| | - N Seki
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo
| | - K Kawakami
- Department of Gastroenterology, Muroran City General Hospital, Muroran
| | - M Sato
- Department of Gastroenterology and Hepatology, Ryuugasaki Saiseikai Hospital, Ryugasaki
| | - K Fujikawa
- Department of Gastroenterology, Hokkaido Cancer Center, Sapporo
| | - T Hirashima
- Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino
| | - T Shimura
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya
| | - K Taku
- Division of Medical Oncology, Shizuoka General Hospital, Shizuoka
| | - T Otsuji
- Department of Gastroenterology, Dongo Hospital, Yamatotakada
| | - F Tamura
- Department of Gastroenterology, Kumamoto Regional Medical Center, Kumamoto
| | - E Shinozaki
- Department of Gastroenterology, Cancer Institute Hospital of JFCR, Tokyo
| | - K Nakashima
- First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki
| | - H Hara
- Department of Gastroenterology, Saitama Cancer Center, Saitama
| | - T Tsushima
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka
| | - M Ando
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya
| | - S Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - N Boku
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki
| | - I Hyodo
- Division of Gastroenterology, University of Tsukuba, Tsukuba
| |
Collapse
|
128
|
Hayashino Y, Suzuki H, Yamazaki K, Goto A, Izumi K, Noda M. A cluster randomized trial on the effect of a multifaceted intervention improved the technical quality of diabetes care by primary care physicians: The Japan Diabetes Outcome Intervention Trial-2 (J-DOIT2). Diabet Med 2016; 33:599-608. [PMID: 26331280 PMCID: PMC5057414 DOI: 10.1111/dme.12949] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/27/2015] [Indexed: 12/25/2022]
Abstract
AIMS To evaluate the effect of multifaceted interventions using the Achievable Benchmark of Care (ABC) method for improving the technical quality of diabetes care in primary care settings. METHODS We conducted a 1-year cluster randomized controlled trial in 22 regions divided into an intervention group (IG) or control group (CG). Physicians in the IG received a monthly report of their care quality, with the top 10% quality of diabetes care scores for all physicians being the achievable benchmark. The change in quality-of-care scores between the IG and CG during follow-up was analysed using a generalized linear model considering clustering. RESULTS A total of 2199 patients were included. Their mean (sd) age was 56.5 ± 5.9 years and the mean (sd) HbA1c level was 56.4 ± 13.3 mmol/mol (7.4 ± 1.2%). The quality-of-care score in the CG changed from 50.2%-point at baseline to 51%-point at 12 months, whereas the IG score changed from 49.9%-point to 69.6%-point, with statistically significant differences between the two groups during follow-up [the effect of intervention was 19.0%-point (95% confidence interval 16.7%- to 21.3%-point; P < 0.001)]. CONCLUSIONS Multifaceted intervention, measuring quality-of-care indicators and providing feedback regarding the quality of diabetes care to physicians with ABC, was effective for improving the technical quality of care in patients with Type 2 diabetes in primary care settings. ( TRIAL REGISTRATION umin.ac.jp/ctr as UMIN000002186).
Collapse
Affiliation(s)
- Y Hayashino
- Department of Endocrinology, Tenri Hospital, Nara, Japan
| | - H Suzuki
- Japan Community Health Care Organization Takaoka Fushiki Hospital, Takaoka, Japan
| | | | - A Goto
- Department of Public Health, Tokyo Women's Medical University, Tokyo, Japan
| | - K Izumi
- Department of Diabetes and Metabolic Medicine, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Noda
- Department of Diabetes Research, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
129
|
Morooka Y, Yamazaki K, Yamada M, Miyamoto S, Sota T, Ishii Y, Hoya K, Ishida Y. Detection of germinoma cells in cerebrospinal fluid using Oct4 immunocytochemistry: a case report. Cytopathology 2016; 27:487-490. [PMID: 26919398 DOI: 10.1111/cyt.12318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/20/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Y Morooka
- Department of Surgical Pathology, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - K Yamazaki
- Department of Surgical Pathology, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - M Yamada
- Department of Surgical Pathology, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - S Miyamoto
- Department of Neurosurgery, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - T Sota
- Department of Neurosurgery, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - Y Ishii
- Department of Neurosurgery, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - K Hoya
- Department of Neurosurgery, Teikyo University, Chiba Medical Center, Ichihara, Japan
| | - Y Ishida
- Department of Surgical Pathology, Teikyo University, Chiba Medical Center, Ichihara, Japan
| |
Collapse
|
130
|
Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Hagio K, Endo Y, Hosoda M, Yamashita H. Abstract P5-08-15: Prognostic value of aldehyde dehydrogenase 1 (ALDH1) and tumor infiltrating lymphocytes (TIL) to predict the late recurrence in ER positive, HER2 negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-08-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Aldehyde dehydrogenase 1(ALDH1) is known to be cancer stem cell marker. Also, tumor infiltrating lymphocytes (TILs) are known to be prognostic factor for triple negative breast cancer. It is reported that these factors have the correlation with chemosensitivity. Meanwhile, the late recurrence (LRec; 5 years after primary surgery) of ER positive breast cancer is the major problem. Significance of expressions of ALDH1 and TILs in primary tumor as predictive factors for late recurrence in ER positive, HER2 negative breast cancer is still unknown.
Methods: ER-positive, and HER2-negative breast cancer patients who underwent surgery or received neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutes belonging the Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. For each LRec patient, approximately two matched control patients without relapse for more than ten years were selected. Expression of ALDH1 was assessed by immunohistochemistry. Positive ALDH1 was defined as tumor including more than 1% cancer cells with ALDH1 expression. TIL was assessed by single whole section according to Denkert's definition. A tumor showing high ki67 and/or low PgR expressions was categorized into Luminal B-like group.
Results: 639 patients (184 with early recurrence (ERec), 134 with LRec and 321 with no recurrence (NoRec)) were analyzed. The rates of positive ALDH1 in ERec, LRec and NoRec groups were 18%, 13% and 8%, respectively. ALDH1 positivity was significantly higher in ERec compared with NoRec group (p<0.01). There was no significant difference between LRec and NoRec group (p=0.12). Positive ALDH1 showed significantly shorter DFS and OS in multivariate analyses (DFS: p=0.03, OS: p<0.01). Especially, that was the significantly prognostic factor in the Luminal B like tumor with adjuvant or neoadjuvant chemotherapy (p=0.01), but not in those without any chemotherapy (p=0.53). High TILs in ERec, LRec and NoRec was 1.1%, 1.5% and 3.7%, respectively. There was no significant difference among three recurrent groups (p=0.13). High TILs was not significantly associated with DFS (p=0.09) and OS (p=0.72). However, there was significant correlation between High TILs and DFS in Luminal B like group (p=0.04) and ALDH1-negative group (p=0.02).
Conclusion: In ER-positive, and HER2-negative breast cancer, ALDH1 was an independent prognostic factor (a predictor of ERec, but not LRec). ALDH1 might be a predictor of benefit from chemotherapy in Luminal B like subtype. TILs was neither a predictor of ERec nor LRec. However, significance of TILs as prognostic factor might differ depending on subtypes and cancer stemness.
Citation Format: Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Hagio K, Endo Y, Hosoda M, Yamashita H. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) and tumor infiltrating lymphocytes (TIL) to predict the late recurrence in ER positive, HER2 negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-15.
Collapse
Affiliation(s)
- Y Miyoshi
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Shien
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - A Ogiya
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Ishida
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - K Yamazaki
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - R Horii
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - Y Horimoto
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Masuda
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - H Yasojima
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Inao
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Osako
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - M Takahashi
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Tomioka
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - K Hagio
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - Y Endo
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - M Hosoda
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - H Yamashita
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| |
Collapse
|
131
|
Nagaya K, Motomura K, Kukk E, Takahashi Y, Yamazaki K, Ohmura S, Fukuzawa H, Wada S, Mondal S, Tachibana T, Ito Y, Koga R, Sakai T, Matsunami K, Nakamura K, Kanno M, Rudenko A, Nicolas C, Liu XJ, Miron C, Zhang Y, Jiang Y, Chen J, Anand M, Kim DE, Tono K, Yabashi M, Yao M, Kono H, Ueda K. Femtosecond charge and molecular dynamics of I-containing organic molecules induced by intense X-ray free-electron laser pulses. Faraday Discuss 2016; 194:537-562. [DOI: 10.1039/c6fd00085a] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We studied the electronic and nuclear dynamics of I-containing organic molecules induced by intense hard X-ray pulses at the XFEL facility SACLA in Japan. The interaction with the intense XFEL pulse causes absorption of multiple X-ray photons by the iodine atom, which results in the creation of many electronic vacancies (positive charges) via the sequential electronic relaxation in the iodine, followed by intramolecular charge redistribution. In a previous study we investigated the subsequent fragmentation by Coulomb explosion of the simplest I-substituted hydrocarbon, iodomethane (CH3I). We carried out three-dimensional momentum correlation measurements of the atomic ions created via Coulomb explosion of the molecule and found that a classical Coulomb explosion model including charge evolution (CCE-CE model), which accounts for the concerted dynamics of nuclear motion and charge creation/charge redistribution, reproduces well the observed momentum correlation maps of fragment ions emitted after XFEL irradiation. Then we extended the study to 5-iodouracil (C4H3IN2O2, 5-IU), which is a more complex molecule of biological relevance, and confirmed that, in both CH3I and 5-IU, the charge build-up takes about 10 fs, while the charge is redistributed among atoms within only a few fs. We also adopted a self-consistent charge density-functional based tight-binding (SCC-DFTB) method to treat the fragmentations of highly charged 5-IU ions created by XFEL pulses. Our SCC-DFTB modeling reproduces well the experimental and CCE-CE results. We have also investigated the influence of the nuclear dynamics on the charge redistribution (charge transfer) using nonadiabatic quantum-mechanical molecular dynamics (NAQMD) simulation. The time scale of the charge transfer from the iodine atomic site to the uracil ring induced by nuclear motion turned out to be only ∼5 fs, indicating that, besides the molecular Auger decay in which molecular orbitals delocalized over the iodine site and the uracil ring are involved, the nuclear dynamics also play a role for ultrafast charge redistribution. The present study illustrates that the CCE-CE model as well as the SCC-DFTB method can be used for reconstructing the positions of atoms in motion, in combination with the momentum correlation measurement of the atomic ions created via XFEL-induced Coulomb explosion of molecules.
Collapse
|
132
|
Matsuda Y, Kato T, Takahashi N, Nakajima M, Arimatsu K, Minagawa T, Sato K, Ohno H, Yamazaki K. Ligature-induced periodontitis in mice induces elevated levels of circulating interleukin-6 but shows only weak effects on adipose and liver tissues. J Periodontal Res 2015; 51:639-46. [DOI: 10.1111/jre.12344] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2015] [Indexed: 12/21/2022]
Affiliation(s)
- Y. Matsuda
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - T. Kato
- Laboratory for Intestinal Ecosystem; RCAI RIKEN Center for Integrative Medical Sciences (IMS-RCAI); Yokohama Japan
| | - N. Takahashi
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - M. Nakajima
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - K. Arimatsu
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - T. Minagawa
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - K. Sato
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
- Division of Periodontology; Department of Oral Biological Science; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - H. Ohno
- Laboratory for Intestinal Ecosystem; RCAI RIKEN Center for Integrative Medical Sciences (IMS-RCAI); Yokohama Japan
| | - K. Yamazaki
- Research Unit for Oral-Systemic Connection; Division of Oral Science for Health Promotion; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| |
Collapse
|
133
|
Komori A, Taniguchi H, Kito Y, Hamauchi S, Masuishi T, Hasegawa H, Mitani S, Narita Y, Kadowaki S, Ura T, Ando M, Mori K, Yasui H, Muro K, Yamazaki K. 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
134
|
Aoyama A, Chen F, Minakata K, Yamazaki K, Yamada T, Sato M, Date H. Sparing Native Upper Lobes in Living-Donor Lobar Lung Transplantation: Five Cases From a Single Center. Am J Transplant 2015; 15:3202-7. [PMID: 26104020 DOI: 10.1111/ajt.13357] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Revised: 03/30/2015] [Accepted: 04/12/2015] [Indexed: 01/25/2023]
Abstract
Living-donor lobar lung transplantation (LDLLT) is indicated for rapidly deteriorating patients, and the total volume of two lower lobe grafts must be sufficient for the recipient. To rescue patients with small lobar grafts, we performed five LDLLTs sparing native upper lobes. This strategy was used when upper lobes or segments were preoperatively less impaired. There were no hospital deaths. Extracorporeal circulation time and operative time were similar to those of conventional LDLLTs. The length of intensive care unit stay was also similar. Late complications attributed to the spared lungs were airway infection in one recipient and pneumothorax in two but they were successfully managed. All recipients were discharged without supplemental oxygen. The spared lung volumes measured by volumetry did not change after LDLLT. Lung perfusion scintigraphy performed at 1 year showed remaining perfusion in the spared lungs, although much less than in the grafts. These results suggested that the spared lobes kept adequate space in the thoracic cavity and kept functioning to a limited extent. The new lobar-sparing strategy appears feasible and effective in LDLLT using small grafts for selected patients when the upper lobes or segments are less impaired.
Collapse
Affiliation(s)
- A Aoyama
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - F Chen
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - K Minakata
- Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - K Yamazaki
- Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Yamada
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Sato
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - H Date
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
135
|
Ishikawa H, Kato T, Yamazaki K, Taku K, Tsushima T, Yoshida Y, Hamauchi S, Yoshikawa S, Yagi H, Kimura M, Kimura M, Nakajo M, Sakata S, Masujima H, Miyazawa A, Izawa M, Iwami K, Yamanaka T, Kiyohara Y. 394P A self-controlled trial of prophylactic topical application of vitamin K1 cream for cetuximab-related skin rash. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv531.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
136
|
Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Todaka A, Yokota T, Machida N, Fukutomi A, Onozawa Y, Muro K, Yasui H, Mori K, Taniguchi H. 165P Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
137
|
Yamazaki K, Kuboki Y, Nishina T, Shinozaki E, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Fukutani M, Nakamoto M, Hasegawa Y, Sugama A, Nomura S, Sato A, Ohtsu A, Yoshino T. 2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31038-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
138
|
Yoshida Y, Yamazaki K, Mizusawa J, Satoh M, Hinoi T, Tsuchida A, Otsuka K, Sato T, Watanabe M, Baba H, Kimura H, Idani H, Kanazawa A, Fukunaga M, Okuda J, Tajima Y, Hasegawa H, Katayama H, Hamaguchi T, Shimada Y. 2129 Predictive factor for toxicities and treatment termination in adjuvant capecitabine therapy for stage III colorectal cancer; based on the data of a randomized trial, JCOG0910. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31051-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
139
|
Van Cutsem E, Obermannova R, Bodoky G, Prausová J, García-Carbonero R, Ciuleanu T, Alfonso PG, Portnoy D, Cohn A, Yamazaki K, Clingan P, Yoshino T, Polikoff J, Lonardi S, Macarulla T, Yang L, Nasroulah F. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31030-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
140
|
Fujita Y, Yamazaki K, Oba M, Muro K, Negoro Y, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Seki N, Sato M, Ebi M, Tamagawa H, Ueda S, Tamura T, Boku N, Hyodo I, Yamanaka T, Tsurutani J, Nishio K. 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31073-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
141
|
Kito Y, Sakamaki K, Yamazaki K, Izawa N, Tsuda T, Morita S, Boku N. 2125 Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31047-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
142
|
Tsushima T, Yamazaki K, Kato T, Taku K, Yoshida Y, Hamauchi S, Yoshikawa S, Yagi H, Kimura M, Ishikawa H, Kimura M, Nakajo M, Sakata S, Masujima H, Miyazawa A, Saitou K, Izawa M, Iwami K, Yamanaka T, Kiyohara Y. 1616 A double blind, self-controlled randomized trial of prophylactic topical vitamin K1 cream application for cetuximab-related skin toxicity (VANQUISH trial). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30704-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
143
|
Yamazaki K, Tsushima T, Shitara K, Sarholz B, Fujita M, Doi T. 365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30228-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
144
|
Cohn AL, Yoshino T, Obermannova R, Bodoky G, Prausova J, Garcia-Carbonero R, Ciuleanu TE, Garcia-Alfonso P, Portnoy D, Van Cutsem E, Yamazaki K, Clingan P, Polikoff J, Lonardi S, Gao L, Yang L, Chang S, Ferry D, Nasroulah F, Tabernero J. 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31045-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
145
|
Abbasi R, Abe M, Abu-Zayyad T, Allen M, Azuma R, Barcikowski E, Belz J, Bergman D, Blake S, Cady R, Chae M, Cheon B, Chiba J, Chikawa M, Cho W, Fujii T, Fukushima M, Goto T, Hanlon W, Hayashi Y, Hayashida N, Hibino K, Honda K, Ikeda D, Inoue N, Ishii T, Ishimori R, Ito H, Ivanov D, Jui C, Kadota K, Kakimoto F, Kalashev O, Kasahara K, Kawai H, Kawakami S, Kawana S, Kawata K, Kido E, Kim H, Kim J, Kim J, Kitamura S, Kitamura Y, Kuzmin V, Kwon Y, Lan J, Lim S, Lundquist J, Machida K, Martens K, Matsuda T, Matsuyama T, Matthews J, Minamino M, Mukai Y, Myers I, Nagasawa K, Nagataki S, Nakamura T, Nonaka T, Nozato A, Ogio S, Ogura J, Ohnishi M, Ohoka H, Oki K, Okuda T, Ono M, Oshima A, Ozawa S, Park I, Pshirkov M, Rodriguez D, Rubtsov G, Ryu D, Sagawa H, Sakurai N, Scott L, Shah P, Shibata F, Shibata T, Shimodaira H, Shin B, Shin H, Smith J, Sokolsky P, Springer R, Stokes B, Stratton S, Stroman T, Suzawa T, Takamura M, Takeda M, Takeishi R, Taketa A, Takita M, Tameda Y, Tanaka H, Tanaka K, Tanaka M, Thomas S, Thomson G, Tinyakov P, Tkachev I, Tokuno H, Tomida T, Troitsky S, Tsunesada Y, Tsutsumi K, Uchihori Y, Udo S, Urban F, Vasiloff G, Wong T, Yamane R, Yamaoka H, Yamazaki K, Yang J, Yashiro K, Yoneda Y, Yoshida S, Yoshii H, Zollinger R, Zundel Z. Measurement of the proton-air cross section with Telescope Array’s Middle Drum detector and surface array in hybrid mode. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.92.032007] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
146
|
Garcia-Carbonero R, Obermannova R, Bodoky G, Prausova J, Ciuleanu TE, Garcia Alfonso P, Portnoy D, Cohn A, Van Cutsem E, Yamazaki K, Al-Batran SE, Rougier P, Liepa A, Yang L, Zhang Y, Nasroulah F, Chang SC, Tabernero J. O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv235.19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
147
|
Nishina T, Kuboki Y, Shinozaki E, Yamazaki K, Kajiwara T, Shitara K, Matsumoto T, Tsushima T, Okamoto W, Mochizuki N, Nomura S, Sato A, Ohtsu A, Yoshino T. PD-017 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv234.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
148
|
Ikeda M, Yamanaka T, Yamazaki K, Yamaguchi K, Muro K, Kusumoto T, Uetake H, Sato T, Kato T, Nishina T, Kanazawa A, Oki E, Chao C, Maddala T, Krishnakumar J, Akagi K, Ochiai A, Ohashi Y, Ohtsu A, Yoshino T. PD-012 Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv234.11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
149
|
Takahashi D, Yamazaki K, Nishida Y, Yamauchi K, Mizushima T. Effects of exercise training in cancer types with low survival rate: systematic review and meta-analysis. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
150
|
Kimura A, Tanabe M, Tajima M, Yamazaki K. The examination of the quantification method of the physical activity of the cerebrovascular handicapped person by wearable camera. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|